Baxter to Present at J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 Jan 26
Source: PRnewswire
Baxter International Inc. shares fell as the stock crossed below its 5-day SMA amid a slight decline in the broader market.
The company announced it will present at the J.P. Morgan Healthcare Conference on January 12, 2026, where CEO Andrew Hider will discuss the latest developments and strategic direction. This event is expected to enhance Baxter's influence in the medical technology sector, potentially boosting investor confidence.
The upcoming presentation highlights Baxter's commitment to transparency and innovation in medical technology, which may attract interest from investors looking for growth opportunities.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 21.73 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





